BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient - Reuters 1 Min Read Sept 13 (Reuters) - Novartis Ag: * DATA SHOW THAT NEURONAL AND GLIAL FILAMENTS, BIOMARKERS OF DISEASE ACTIVITY, HAVE POTENTIAL TO SUPPORT DECISION MAKING IN MANAGEMENT OF MULTIPLE SCLEROSIS (MS) PATIENT * THESE DATA FURTHER SUPPORT USE OF NEURONAL AND GLIAL FILAMENTS AS GUIDES TO HELP PHYSICIANS AND PATIENTS WITH DISEASE MANAGEMENT Further company coverage: (Berlin Speed Desk) All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. ÂÅ 2019 Reuters. All Rights Reserved. BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient Sept 13 (Reuters) - Novartis Ag: * DATA SHOW THAT NEURONAL AND GLIAL FILAMENTS, BIOMARKERS OF DISEASE ACTIVITY, HAVE POTENTIAL TO SUPPORT DECISION MAKING IN MANAGEMENT OF MULTIPLE SCLEROSIS (MS) PATIENT * THESE DATA FURTHER SUPPORT USE OF NEURONAL AND G
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director [Yahoo! Finance]Yahoo! Finance
- Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential' will drive long-term growth [Fortune]Fortune
- BerGenBio Appoints Olav Hellebø as CEO [Yahoo! Finance]Yahoo! Finance
- Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies [Yahoo! Finance]Yahoo! Finance
- NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website